Inhibition of chemiluminescence by carvedilol in the cell-free system, whole human blood and blood cells

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 65, Issue 1, 2005, Pages 55-64

  Nosal, Rado ^a   Jancinova, V ^a   Ciz, M ^b   Drabikova, K ^a   Lojek, A ^b   Fabryova, V ^c  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Blood platelets; Carvedilol; Chemiluminescence; Myeloperoxidase; PMN leucocytes; Reactive oxygen species; Whole blood

Indexed keywords

CALCIMYCIN; CARVEDILOL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; HYDROGEN; HYDROXYL RADICAL; LUMINOL; MYELOPEROXIDASE; PEROXIDE; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; RECEPTOR; SEROTONIN; SUPEROXIDE;

ADULT; ARTICLE; BLOOD; BLOOD CELL; CELL FREE SYSTEM; CHEMOLUMINESCENCE; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; NEUTROPHIL; PRIORITY JOURNAL; THROMBOCYTE;

ADULT; BLOOD CELLS; BLOOD PLATELETS; CARBAZOLES; CELL LINE, TUMOR; CELL-FREE SYSTEM; CHEMILUMINESCENT MEASUREMENTS; ENZYME INHIBITORS; HUMANS; KINETICS; LEUKOCYTES; MALE; MIDDLE AGED; PEROXIDASE; PROPANOLAMINES; REACTIVE OXYGEN SPECIES;

EID: 14044250171     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510410003084     Document Type: Article

References (30)

1. Savitz SI, Erhardt JA, Anthony JV, Guypta G, Li X, Barone FC, Rosenbaum DM. The novel β-blocker, carvedilol provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 2000;8:1197-204.
2. Feuerstein GZ, Bril A, Ruffolo RR Jr. Protective effect of carvedilol in the myocardium. Cardiology 1977;80:41-55.
3. Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol. Rationale for use in hypertension, coronary heart disease and congestive hean failure. Cardiovasc Drugs Ther 1997;11:247-56.
4. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaced therapeutic potential. Cardiovasc Drug Rev 2001;2:152-71.
5. Yue T-L, Wang X, Gue JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995;273:1442-9.
6. Feuerstein G, Liu G-L, Yue T-L, Cheng H-Y, Hieble JP, Arch JRS, Ruffolo RR Jr, Ma X-L. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur J Pharmacol 1998;351:341-50.
7. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino C Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000;101:122-4.
8. Petrikovâ M, Jancinovâ V, Nosál' R, Májeková M, Danihelová E. Antiplatelet activity of carvedilol in comparison to propranolol. Platelets 2002;13:479-85.
9. 2). Thromb Res 2002;105:339-45.
10. 1-antagonist Dithiaden® in human PMN leukocytes. Free Rad Res 2002;36:975-80.
11. Lojek A, Číž M, Slaviková H, Dušková M, Vondráček J, Kubala L, Rácz I, Hamar J. Leukocyte mobilization, chemiluminescence response and antioxidative capacity of the blood in intestinal ischemia and reperfusion. Free Rad Res 1997;27:359-67.
12. Jančinovǎ V, Drábiková K, Nosál' R, Petriková M, Číž M, Lojek A. Danihelová E. Inhibition of FMLP-stimulated neutrophil chemiluminescence by blood platelets increased in the presence of the serotonin-liberating drug chloroquine. Thromb Res 2003;109:293-8.
13. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase and bacterial killing. Blood 1998;92:3007-17.
14. Furtmüller PG, Obinger C, Hsuanyu Y, Dunford HB. Mechanism of reaction of myeloperoxidase with hydrogen peroxide and chloride ion. Eur J Biochem 2000;267:5858-64.
15. Arnholdt J, Furtmüller PG, Regelsberger G, Obinger C. Redox properties of the couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur J Biochem 2001;268:5142-8.
16. Nakamura M, Nakamura S. One- and two-electron oxidations of luminol by peroxidase systems. Free Rad Biol Med 1998;24:537-44.
17. Gao F, Chen J, Lopez BL, Christopher TA, Gu J, Lysko P, Ruffolo RR Jr, Ohlstein EH, Ma XL, Yue TL. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 1998;351:341-50.
18. Wittmann S, Frölich D, Daniels S. Characterization of the human fMLP receptor in neutrophils and in Xenopus oocytes. Br J Pharmacol 2002;135:1375-82.
19. Takahashi R, Edashige K, Sato EF, Inoue M, Matsuno T, Utsumi K. Luminol chemiluminescence and active oxygen generation by activated neutrophils. Arch Biochem Biophys 1991;285:325-30.
20. Weisdorf DJ, Thayer MS. Occult intracellular calcium pools: relevance to neutrophil oxidant production. J Lab Clin Med 1989;114:260-5.
21. Smith R, Justen JM, Sam LM. Function and stimulus-specific effects of phorbol 12-myristate 13-acetate on human polymorphonuclear neutrophils: autoregulatory role for protein kinase C in signal transduction. Inflammation 1988;12:597-611.
22. Jančinová V, Nosál' R, Drábiková K, Danihelová E. Cooperation of chloroquine and blood platelets in inhibition of polymorphonuclear leukocyte chemiluminescence. Biochem Pharmacol 2001;62:1629-36.
23. Feuerstein G, Schusterman NH, Rufollo RR Jr. Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997;33:453-73.
24. Varin F, Cubeddu LX, Powel JR. Liquid Chromatographic assay and disposition of carvedilol in healthy volunteers. J Pharm Sci 1986;75:1195-7.
25. Yue TL, McKenna J, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilating β-adrenoceptor blocking antihypertensive drug protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res 1994;28:400-6.
26. Habon T, Szabados E, Kesmarky G, Halmosi R, Pat T, Sumegi B, Toth K. The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. Cardiovasc Res 2001;52:153-60.
27. Ross D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microb Infect 2003;5:1307-15.
28. Asbrink S, Zickert A, Bratt J, Gyllenhammar H, Palmblad J. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of Superoxide ions. Biochem Pharmacol 2000;59:1007-13.
29. 2 for activation of the phagocyte NADPH oxidase. J Biol Chem 1998;273:441-5.
30. Nosál' R, Drábiková K, Jančinová V, Číž M, Lojek A. Histamine, dithiaden and human polymorphonuclear leukocytes in vitro. Inflamm Res 2003;52:S19-20.